Wockhardt Limited — Investor Meet, 11-06-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Wockhardt reported INR 3,373 Cr revenue, INR 630 Cr EBITDA (up 51%), and INR 238 Cr PBT. The net debt-to-equity ratio is 0.1, with EBITDA margin improving from 5.4% to 18.6%. Management highlighted Zaynich, the first Indian R&D product with US FDA approval, as a major growth engine. The company projects Zaynich's global peak sales at $1.5-2 billion per year. Wockhardt is focused on novel antibiotics, diabetes biosimilars (aiming to double business in 2-3 years), and core pharma segments. The company exited its loss-making US generics business, confident about a new growth phase driven by innovation and financial strength.